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Abstract 
Background: In vivo imaging using fluorescence is used in cancer biology for the detection, measurement and 
monitoring of tumours. This can be achieved with the expression of fluorescent proteins such as iRFP, which emits 
light at a wavelength less attenuated in biological tissues compared to light emitted by other fluorescent proteins 
such as GFP or RFP. Imaging platforms capable of detecting fluorescent tumours in small animals have been devel-
oped but studies comparing the performance of these platforms are scarce.
Results: Through access to three platforms from Xenogen, Bruker and Li-Cor, we compared their ability to detect 
iRFP-expressing subcutaneous tumours as well as tumours localised deeper within the body of female NSG mice. 
Each platform was paired with proprietary software for image analyse, but the output depends on subjective deci-
sions from the user. To more objectively compare platforms, we developed an ‘in house’ software-based approach 
which results in lower measured variability between mice.
Conclusions: Our comparisons showed that all three platforms allowed for reliable detection and monitoring of sub-
cutaneous iRFP tumour growth. The biggest differences between platforms became apparent when imaging deeper 
tumours with the Li-Cor platform detecting most tumours and showing the highest dynamic range.
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Introduction
Precise imaging and serial measurement of mouse 
tumours is important across a range of cancer research 
projects. For palpable, subcutaneous tumours, calli-
per measurements (in which the length and diameter 
of the tumour gives an estimate of its volume) is one 
of the most used methods for routine assessment of 
tumour progression [1, 2]. For deeper tumours that are 
not palpable, imaging techniques such as MRI, X-ray, 
fluorescent microscopy or luminometry are used [3]. 
Of these, the most commonly used technique in pre-
clinical research is luminometry which requires an 
enzymatic luciferase reaction for visualisation. This 
technique can be used on injected cells expressing 
constitutive or inducible luciferase, in genetically engi-
neered mouse models or using injected viruses that 
carry the luciferase gene. In practice, the d-luciferin 
substrate is usually injected in the scruff of the mouse 
and allowed to circulate for 5–10 min while the mouse 
is active before anaesthesia, after which images can 
be acquired using a CCD based imaging platform. 
The drawback of this approach is the requirement for 
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to an otherwise non-invasive technique. The researcher 
then has to allow time for the production of lumines-
cence through the luciferase reaction. The optimal time 
to measure tumour size and location within the animal 
is within ~ 10 min of the injection [4, 5], but variations 
in how much d-luciferin is injected or diffuses into the 
bloodstream to reach the tumour, and how much time 
elapses before imaging can lead to variation in meas-
urements. Timing d-luciferin injections so that every 
animal is measured at the same time after administra-
tion, especially if multiple animals are measured at the 
same time, can be challenging and time consuming. 
This variability has been shown to have a significant 
amount of change in luminescence output in the early 
time period after injection [4, 5]. However, used care-
fully, luciferase can be an excellent imaging tool with 
low background and a very high sensitivity in detecting 
tumours.
Fluorescent proteins, such as GFP (green fluorescent 
protein, 510 nm emission peak), mCherry (610 nm emis-
sion peak [6]) and mStrawberry (596 nm emission peak 
[6]) are generally stably or inducibly expressed in the cell 
lines from which a tumour can be established. Similarly 
to luciferase, they may also be induced using viruses car-
rying the fluorescent protein’s coding sequence. A set-
back of using fluorescence is autofluorescence in animals, 
caused by tissues or the diet [7]. Low-autofluorescence 
feed is available and has been demonstrated to reduce 
background to some extent [7]. Luciferase signal is usu-
ally stronger than fluorescent signals, due to its typically 
longer capture period, lack of photobleaching and wider 
imaging spectrum, allowing detection of weaker or atten-
uated signals (through hair, pigmentation, or tumour 
depth). For this reason, D-luciferin is often used in stud-
ies where the signal may be weak or located deep within 
the body. Like other fluorescent proteins, the near-infra-
red fluorescent protein iRFP avoids the variability due to 
dose and time factors of d-luciferin injections, as well as 
welfare concerns related to the additional injection. As 
its wavelength falls outside the absorption spectrum of 
haemoglobin and oxy-haemoglobin (found extensively 
in mammalian tissues), the iRFP signal is less attenuated 
in tissues and therefore has better signal to background 
ratios than other fluorescent proteins [8].
There are a number of iRFP proteins, but the first and 
most widely used is iRFP713, which has an emission peak 
at 713  nm [9]. Infrared proteins utilise biliverdin as a 
chromophore and iRFP713 requires endogenous biliver-
din to become fluorescent [9]. iRFP713 has been used to 
image single cells as well as organs and tumours in whole 
organisms in real time [9–12]. Various research groups 
have successfully used iRFP to monitor tumour growth or 
to detect and monitor formation of metastasis [9, 12–20]. 
Other iRFP variants exist (iRFP670, miRFP680, iRFP682, 
iRFP702 and iRFP720), which all have slightly differing 
excitation and emission spectra [21–23].
Here, we directly compare the performance of three 
in-vivo imaging platforms to track tumours over a two-
week time period. We used the Xenogen VivoVision IVIS 
200 (XVI), Bruker In-Vivo Xtreme (BIX) and the Li-Cor 
Pearl Trilogy (LPT) to examine growth of subcutaneous 
tumours and deep tissue tumours arising from tail vein 
injections of iRFP-expressing cancer cell lines. All plat-
forms are able to measure subcutaneous iRFP tumours 
reliably, but deep-tissue tumours were detected to vari-
able degrees by each of the three platforms, with the LPT 
detecting most tumours.
Results
Determining the dynamic range and signal linearity of all 
platforms
In order to test the dynamic range of the three different 
imaging systems: Xenogen VivoVision IVIS 200 (XVI), 
Bruker In-Vivo Xtreme (BIX) and Li-Cor Pearl Trilogy 
(LPT), we created a point source test, mimicking a sub-
cutaneous tumour-like situation in which we could con-
trol the amount of fluorescence in a linear manner. We 
generated a 10 × dilution series of iRFP-expressing A431 
cells as a representative for iRFP-expression (these cells 
express high levels of iRFP, Fig.  1a) or a near-infrared 
secondary antibody (680RD) with similar excitation and 
emission spectra to iRFP (Fig. 1b) by dilution in agarose 
in a 96-well plate. The dilutions aimed to be in the low-
end of detection range, so as to best find a limit of detec-
tion for small tumours. Of all machines, the LPT detects 
the most linear range with the iRFP-expressing cells or 
the 680RD-coupled antibody. Of note, the LPT saves 
images at 22-bit while the other platforms use 16-bit 
(Fig. 1a, b). However, it should be noted that the lowest 
visible dilution against background when using false col-
ours is the same for both the LPT and the XVI (Fig. 1a) 
and only marginally better in the LPT for the antibody 
dilution (Fig.  1b). This is important as decisions (gating 
and tumour delineation) are usually taken using subjec-
tive visual clues when analysing tumours in mice. Before 
testing the performance of the platforms with mice, we 
next wanted to determine if the signal was stable or sub-
ject to photobleaching by repeated measurements. We 
therefore measured the test plate again in the LPT after 
all tests and acquisitions were completed on the other 
platforms. Even after multiple test exposures between 
5 and 60  s were performed on all platforms, the results 
indicate that there is no qualitative difference between 
the first or final readings, and that photobleaching of 
iRFP caused by repeated measures would not cause 
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differences between platform measurements (Additional 
file 1: Fig. S1A).
iRFP signals in subcutaneous tumours
H1299 cells stably expressing iRFP were injected subcu-
taneously into mice. The volume of resulting tumours 
was estimated using calliper measurements, and imaged 
for infrared fluorescence over time as indicated in Fig. 1c. 
Subcutaneous tumour growth was followed using calli-
per measurements from the first day that tumours were 
palpable (day 4 after injection) and then biweekly. These 
measurements showed statistically significant increases 
in growth from day 15 to day 18, but not from day 18 to 
day 22 (Fig. 1d).
iRFP was imaged on the days preceding the calliper 
measurements. On all three different imaging platforms, 
mice were positioned laterally so that the tumour faced 
the camera. Specifications and differences between 
machines are listed in Additional file  2: Tables S1 and 
S2. To determine background, we quantified the fluores-
cence of an area of the mouse without tumour between 
the neck and upper torso, which was highly similar in 
all mice and all time points. Since the LPT displayed the 
highest dynamic range (Fig.  1a, b), we examined how 
background changed across a mouse and over time on 
this platform. Contrary to the XVI and BIX, the LPT was 
able to clearly separate the mouse background from the 
basal background of the imaging bed (visible in Fig. 2c, f ). 
Of note, this results in a lower apparent tumour signal in 
the 3D representations, because the mouse background 
is clearly above basal background. The 3D representa-
tions per mouse highlight that the mouse background 
signal is uniform in all platforms. In addition, the back-
ground does not change over the four measuring days 
(Additional file 1: Fig. S1B).
A significant increase in tumour growth from day 
17 to day 24 was seen and measured on all platforms 
(Fig. 1e–j) (due to incorrect set up of filters on the XVI, 
measurements of day 14 could not be used). Absolute 
fluorescence intensity was highly variable between plat-
forms since each platform’s analysis software has a differ-
ent method for calculating and displaying fluorescence 
intensity. To illustrate objective differences between plat-
forms, we exported the raw TIFF files from each platform 
and plotted the data into a 3D model in Mathematica 
(MouseTensity) where Z-height is based on fluorescent 
intensity. The resulting images from three mice imaged 
on day 24 with each platform are shown in Fig.  2a–c. 
The 3D nature of the projection shows background and 
signal at the same time, and this allows users to more 
effectively and more intuitively select a region of interest 
as shown for mouse 2 at day 24 (Fig.  2d–f). 3D projec-
tions obtained from all mice on day 17 and day 24 from 
the raw signal are shown in Additional file  1: Figs. S2 
and S3. After selecting tumour boundaries, guided by 
the 3D representation, we then calculated the intensity 
in each tumour and plotted these in a similar manner to 
Fig. 1e–g (Fig. 2g–i).
Despite the varying absolute fluorescent intensities 
between different platforms, a similar fold increase of 
about 6-fold in tumour growth over time (day 17–24) 
was measured using all platforms, regardless of the 
analysis used (Fig. 2j). This fold increase was generally 
lower, 2.5-fold, using Mathematica than the proprietary 
software. Furthermore, signal intensity measurements 
using Mathematica have a lower variation (Fig. 2k) than 
observed using propriety software programs (Fig.  2k) 
as measured by the coefficient of variance (Fig.  2k). 
The consequence of this finding was that the increased 
tumour growth between days 17–21, previously non-
significant (at a 95% confidence interval) in the LPT 
(Fig.  1g), was significant at a 95% confidence interval 
when the images were reanalysed with Mathematica 
and p-values were generally smaller (Fig. 2i; Additional 
file  2: Table  S3. The lower fold-changes using Math-
ematica for days 17–21 (XVI: 1.8x, BIX: 1.7x, LPT: 2.4x) 
(See figure on next page.)
Fig. 1 a, b Normalised signal of a logarithmic dilution of fixed iRFP expressing A431 cells (a) or iRFP antibody (680RD) (b), suspended in low-melt 
agarose, and a representative example of each dilution series as seen by each platform. Gating was performed to be able to see the lowest 
possible dilution above background. A representative example of one of the triplicates imaged in each platform is shown below the graph. 
Arrows represent the subjective last visible dilution using gating optimised to see the lowest possible signal distinguishable from background. 
LPT = Li-Cor Pearl Trilogy, BIX = Bruker In-Vivo Xtreme, XVI = Xenogen VivoVision IVIS 200. Quantification was performed in each platform’s own 
software and results of technical triplicates with standard deviation error bars are shown. Points without error bars have an error too low to be 
rendered in Prism. c Schematic representation of calliper measurements (blue triangles) and imaging measurements (green triangles) in days after 
subcutaneous injection of iRFP expressing H1299 cells. d Tumour volume over time as measured by callipers. Error bars represent ± SD, (asterisk 
indicates Tukey’s multiple comparisons test p < 0.05, NS p > 0.05). e–g Measurements of fluorescent intensity of tumours over time as measured 
by the XVI (fluorescent intensity: radiant efficiency) (e) BIX (fluorescent intensity: counts) (f) or the LPT (fluorescent intensity: signal) (g). Error bars 
represent ± SD, (asterisk indicate statistically significant differences, ANOVA, Tukey’s multiple comparisons test p < 0.05, NS indicates no significant 
difference). h–j Images of the tumour of mouse 2 on each measurement day for the XVI (h), BIX (i) and LPT (j). Images show fluorescent intensity 
as shown by each platform’s software (false colours mode) overlaid on brightfield images, to show example of tumour growth. Scale bars for each 
software are presented. XVI was gated to day 17, BIX and LPT were gated to day 14
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compared to proprietary software (XVI: 3.7x, BIX: 4.1x, 
LPT: 3.6x) were more consistent with the calliper vol-
ume estimations for days 18–22 (1.5 ×) and may pro-
vide a more linear comparative tumour size estimate. 
These analyses also suggest that images taken using 
each platform hold similar information and are more 
comparable across platforms in terms of variation or 
signal to noise ratios than was expected. Overall, these 
data infer that for superficial tumours, any of these 
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Fig. 2 a–c Mouse tumour intensity outputs from MouseTensity of data captured on the XVI (a), the BIX (b) or the LPT (c) on day 24. Mouse 1, 2 
and 3 are shown, grouped by cage in the XVI and the BIX. Mouse 1, 2 and 3 are shown separately as the images are acquired per mouse in the LPT. 
The highest intensity in each image is normalised to 1. (S.U.: Standardised Unit) A colour scale indicating highest and lowest values in indicated 
on the top right of A. d–f Representative example of mouse 2 on day 24. Data from XVI (d), BIX (e) or LPT (f) are visualised (S.U.: Standardised Unit). 
The section coloured rainbow is used as the measurement signal, while the monochrome purple is considered noise. The difference is delineated 
by a yellow line. g–i Measurements of fluorescent intensity of tumours over time as measured by the XVI (g) the BIX (h) or the LPT (i). Error bars 
represent ± SD, (ANOVA: asterisk indicates Tukey’s multiple comparisons test p < 0.05, NS p > 0.05). j Fold increase from average tumour size on day 
17 to average tumour size on day 24. Measurements were calculated with each platform’s software. Error bars represent + SD. k Coefficients of 
variance for the software provided with each platform. Coefficient of variance was measured as a function of the final day. Error bars represent + SD
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Notably, the brightest portion of the tumour images in 
the XVI sometimes clipped the upper limits of detection 
(Additional file  1: Fig. S4A). In retrospect, the default 
“medium” binning setting on the XVI was misleading to 
the user as in reality this can be considered high (8 × 8 
binning). This binning results in a multiplication of the 
signal intensity by 64 compared to no binning, enhanc-
ing the potential of signal clipping. Of note, the lowest 
possible binning setting for the XVI is 4 × 4. Each plat-
form was set up on the first day to measure tumours with 
identical settings used on each following day, in order to 
enable comparison of all intensities over that time period. 
The dynamic range remained unsaturated for both the 
LPT and the BIX platforms, possibly accounting for the 
highest fold increases observed.
When comparing tumour growth in individual mice, 
the LPT was more similar to the XVI (Additional file 1: 
Fig. S4B–D), consistently showing the lowest growth in 
mice 2 and 5, and fastest tumour growth in mice 1, 4 and 
6. Although the BIX measurements showed the same 
trend, mouse 6 measurements were substantially higher 
throughout the experiment compared to the other mice. 
Notably, the tumour in mouse 3 did not increase in vol-
ume by calliper measurements across the experimen-
tal timeframe, although all imaging platforms detected 
increased growth (Additional file  1: Fig. S4B–E). Post-
mortem this tumour was growing flatter and more inva-
sively into the muscle, making it harder to detect with 
callipers. As a possible consequence, tumour growth was 
not significantly changed over days 18–22 with callipers, 
while via iRFP analysis in the LPT (Mathematica) was 
significant over days 17–21 (Fig. 1d).
Detection of iRFP in deep tissues
For subcutaneous tumours, imaging was started when 
tumours were palpable, precluding determination of dif-
ferences in early sensitivity between imaging platforms. 
To determine how each platform performed on tumours 
that were not palpable, iRFP-expressing H1299 cells were 
injected in the tail vein of 6 mice, numbered mouse 7 
to mouse 12, and allowed to form tumours. H1299 cells 
were expected to settle and grow in liver, lung and bone 
as previously reported [24, 25]. iRFP expression was 
measured on the 3 platforms on 31, 34, 38 and 41  days 
after injection (Fig.  3a) (similarly to the subcutaneous 
tumours, iRFP filters for the XVI were wrongly cho-
sen on day one thus images were not usable). Mice were 
positioned in a ventral position in respect to the detec-
tor. Images of mouse 8 in all platforms and all days are 
depicted in Fig. 3b and images of all 6 mice in each plat-
form on day 41 are shown in Additional file  1: Fig. S5. 
Mice were sacrificed after imaging on day 41 and post-
mortem investigations were carried out to determine 
total tumour burden. Identified lesions are reported in 
Additional file  2: Table  S4 and bright-field images are 
shown in Additional file 1: Fig. S5B.
As expected, during imaging abdominal tumours were 
detected in most mice (Additional file  1: Fig. S5A) and 
two limb metastases were detected in mouse 8 (Fig. 3b). 
Whole body imaging did not detect any metastases in 
the chest in the timespan of our experiment. To visual-
ise the earliest measurement day on which each platform 
detected a certain signal, we displayed this as a heat map 
in Fig. 3c. Notably, this figure does not show all signals. 
We have shown images from all mice on the final day 
of imaging in Additional file 1: Fig. S5A. This shows the 
most comprehensive cohort of tumours. The only sig-
nal not apparent on day 41 is the abdominal signal of 
mouse 10. The LPT detected most signals across all mice, 
although the BIX detected the fluorescent signal from 
the abdomen of mouse 12 one timepoint earlier than the 
LPT. The BIX detected most signals on day 31 but did 
not detect the abdominal tumour signal of mouse 10 on 
any of the 4  days. The XVI detected each tumour later 
than the other two systems. Though this is in part due 
to the missed measuring day, it missed 3 of the tumours 
on day 34 (mouse 8 abdominal, mouse 9 abdominal and 
mouse 11 abdominal), which were detected by the other 
platforms. It was also not able to detect the knee tumour 
seen in mouse 8, which was seen by other platforms more 
than 1 week earlier (Fig. 3c).
We next harvested livers, lung and any additional 
tumours found post mortem (Fig.  4a; Additional file  1: 
Fig. S5B). We imaged these organs after dissection, which 
allowed us to measure each platform’s ability to resolve 
very small tumours and better detect the location of the 
tumours detected in whole body imaging. Fluorescence 
was readily detected in the livers of all mice on all plat-
forms and brightest in mouse 7 and 11. Interestingly, flu-
orescence in the whole-body imaging abdomen of mice 
7, 8 and 12 was most pronounced (Additional file 1: Fig. 
S5A). The liver tumours of mouse 10 were only detected 
using the LPT and the XVI on day 34 in the whole-body 
imaging (Figs. 4a, 5a; Additional file 1: Fig. S5A). Ex vivo, 
the signal of this tumour was a bit more localised to one 
area of the liver (Fig.  4a). Histology also suggested that 
this liver had less large tumour areas than most of the 
other livers (Fig. 4c).
Our analyses of whole-body images also revealed 
that none of the platforms could detect lung tumours, 
although post mortem, lung puncta were visible in 
excised lungs of all mice (Fig. 4a, c; Additional file 1: Fig. 
S5B). Fluorescent puncta were most clearly observed 
with the LPT, which was able to image a large number of 
distinct foci in each harvested lung, whereas both the BIX 
and XVI only showed an indistinct mass of fluorescence 
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across the organ. The XVI did not detect lung signals in 
2 of the 6 mice (mouse 9 and 11). The LPT and the BIX 
were unable to detect lung tumours one mouse, mouse 
8 and mouse 11 respectively, though there were tumours 
found in those lungs as can be seen in histology (Fig. 4c). 
Bone tumours in the paw and knee of mouse 8 (Fig. 3b) 
were also confirmed after dissection and imaging of the 
individual affected limbs (Additional file  1: Figs. S5B, 
S6A).
During imaging of tumours in each organ, a different 
background fluorescence was noted on each platform, 
which might be caused by slight differences in filter sets 
of each platform (Additional file 2: Table S1). In particu-
lar, the XVI and BIX both showed a very homogenous 
fluorescence across the whole brain, but the LPT did not 
(Fig.  4b). The XVI additionally detects high fluorescent 
background in all organs, that is less prominent in either 
the LPT or the BIX. The spleen had a higher background 
fluorescence than other organs in all platforms. In prac-
tice, this means that the LPT might be more suited to 
detect brain tumours, but that for all tumours back-
ground measurements for individual organs must be con-
sidered when quantifying tumours in that organ.
In order to quantify how well each machine per-
formed to detect tumours, we calculated the per-
centage of detected tumours in whole body scans 
(Additional file  2: Table  S4) compared to the actual 
number of tumours detected ex  vivo in the individual 
organs (Fig.  4a, c Additional file  1: Fig. S5A, Addi-
tional file  2: Table  S4). In total, ex  vivo, we detected 
tumours in all 6 livers, all 6 lungs and 2 tumours in 
limbs. Although different nodules were detected in 
the liver, abdominal tumours were scored as one 
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Fig. 3 a Schematic representation of imaging days after tail vein injections. Organs were imaged independently on the last day. b Comparison of 
images of mouse 8 taken on each imaging day per platform. BIX mice are positioned resting on their abdomen on a glass surface with the picture 
taken from underneath, while in both other platforms, the mice are positioned on their backs with the image taken from above. Colour bars reflect 
highest and lowest values from top to bottom. c Heatmap depicting the earliest day that tumours were visible. Crosses are used to represent lesions 
which were not picked up by that platform by the end of the experiment

























Fig. 4 a Ex-vivo images of the lungs and livers for all mice in each platform. Colours are false colours as applied by platform specific software with 
the scales indicating highest and lowest values on the right. b Brain of mouse 7 and spleen of mouse 10 imaged by each platform. c Histological 
H&E sections of lungs and livers are shown as whole organs (left) or a zoom of one the tumours (right) for each mouse
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machine was able to find these tumours in the ‘whole 
body’ images and calculated the percentage of detected 
tumours (Additional file  2: Table  S4). Not account-
ing for the images taken on day 31, these data suggests 
that the XVI is the least sensitive platform for detecting 
deep fluorescent signals, while the BIX and LPT per-
formed at similar levels with the LPT detecting margin-
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Fig. 5 a Binary heatmap showing whether a tumour was or was not detected on a given day by each platform. Notably, lesions in the abdomen 
are scored as one lesion although in some mice more than one signal was noted on certain days. Annotation: mx-position, where x is the mouse 
number and position is a rough anatomical position seen in whole body imaging. b LPT images showing the disappearance and re-appearance 
of the abdominal tumour of mouse 9. All images are gated to day 31. c Example of positioning of the phantom mouse in the BIX. White text 
is artefactual from software and may be disregarded. d Variation in signal of the phantom mouse iRFP, seen in the three imaging platforms, 
normalised to 1. e coefficient of variance of phantom mouse iRFP in each platform
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Once a tumour was detected, it was not always pos-
sible to re-detect it on subsequent days. To evalu-
ate detection dynamics, we graphed the presence or 
absence of tumours in each platform using a binary heat 
map (Fig.  5a). Missing tumours in this graph could be 
the result of a very low signal, which if close enough to 
background, could appear and disappear between imag-
ing sessions. Alternatively, positioning of the mice could 
be of importance to detect some tumours. Figure  5b 
shows an example in the LPT, where the front paw of 
the animal is slightly more upwards on days 31 and 41, 
but downwards on the intermittent measuring days. As 
images were taken blindly, we only noticed this subtle 
difference upon analyses. As the signal on day 31 is well 
above background, positioning seems to affect tumour 
detection. We therefore wanted to determine how much 
variation we could create by changing the position of a 
phantom mouse with a signal close to the iRFP spectrum 
(Alexa Fluor 680) (Fig. 5c) and how important the maxi-
mum variation would be in each machine. The phantom 
mouse, used to calibrate machines, is a plastic mouse 
shaped object with cavities at various depths into which 
fluorescence-coated probes can be inserted to check how 
well a mouse can be imaged with this probe. The signal 
was normalised to 1 to be able to display the variation of 
each platform next to each other (Fig. 5d) and the coef-
ficient of variance was calculated (Fig. 5e). These results 
indicate that the highest variation was seen in the XVI 
with 35% variation and the lowest in the LPT 20%. Posi-
tioning differences are therefore a limiting factor for the 
accurate detection of small visceral tumours, making 
quantification of such deep tissue tumours difficult and 
highly variable.
Discussion
We evaluated the performance of different iRFP imaging 
platforms to quantify growth of subcutaneous tumours 
and detect deep-tissue tumours arising from injected 
iRFP expressing cells. Comparing three platforms, the 
Xenogen VivoVision IVIS 200 (XVI), the Bruker In-Vivo 
Xtreme (BIX) and the Li-Cor Pearl Trilogy (LPT), it is 
clear that all three are able to measure iRFP expressed in 
tumours, but that each individual platform has features 
which might suit certain experiments better than others 
(Additional file 2: Table S1).
The level of fluorescence in a cell or tissue is depend-
ent on a variety of factors including gene copy number, 
the activity of the promotor and protein stability, which 
all lead to differences in fluorescence that affect meas-
urements. To rule out such variations, we compared 
tumours established from cells expressing high and stable 
levels of iRFP. Here we used iRFP713, the most frequently 
used construct in near-infrared imaging. Many studies 
have used the IVIS imaging systems to study deep-tissue 
tumours [10, 17–20], a smaller number have used the 
LPT [11, 14] and others have used custom-built machines 
[15, 21]. The BIX imaging system has been used to study 
iRFP expression in mice, for example to study adipose tis-
sue [26], but we found no reports on its use for tumour 
growth or metastasis using iRFP.
The most frequently used method for subcutaneous 
tumour measurements is using callipers. Previous com-
parisons between GFP fluorescence and tumour volume 
showed a good correlation between these parameters 
[27, 28]. We also observed that careful, objective iRFP 
measurements showed variation similar to calliper meas-
urements. However, one tumour was not picked up as 
growing using calliper (mouse 3), but was detected grow-
ing in all imaging platforms. This tumour was flatter and 
invasive into the muscle, something that can happen 
dependent on the injection and the cell type one inves-
tigates and points towards an advantage for fluorescent 
imaging. While the callipers estimated a 1.5-fold increase 
in tumour volume, the imaging platforms with propri-
etary software generally measured between a 3.6- and 
4.1-fold increase in fluorescence intensity as a surrogate 
of tumour volume. This seemed mainly due to an overes-
timation of intensity in the proprietary software possibly 
due to user misjudgements in subjective gating, as analy-
ses of raw images with 3D-guided gating using our Math-
ematica applet showed a 1.7–2.4-fold increase in tumour 
growth over the same days. In an experimental setting, 
proprietary software analysis could therefore lead to an 
overestimation of the actual differences between experi-
mental conditions.
Another consideration is that images in the XVI 
reached the maximum intensity at the last day and the 
BIX was close to reaching this maximum limit. Exposure 
time, aperture or binning can be changed to avoid image 
saturation, but this would lead to difficulties in compar-
ing the intensities between days. Determining constant 
settings ahead of time is difficult, especially when the 
total dynamic range of a given platform is low. Although 
theoretically this can be compensated for as fluorescent 
emission is linear in time, in practice day-to-day variation 
such as feeding state or urine volumes will lead to varia-
bility in measurements. According to marketing material, 
and confirmed experimentally, the LPT has an advantage 
of a larger dynamic range by internally combining several 
exposures, and is therefore able to image at the same set-
tings throughout an experiment without saturating.
One of the biggest challenges in determining growth 
of tumours in  vivo, is setting the intensity thresholds 
(gating) to help define tumour boundaries. For exam-
ple, images can be gated to show signal in the small-
est tumour on the first day of imaging, with settings 
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maintained to gate each subsequent image. Alternatively, 
images can be gated on the last day to show the grown 
tumours, with the same settings applied to each pre-
ceding day. This can result in drastic differences in the 
visualisation of the tumours, and therefore in defining 
their boundaries and determining their signal intensity. 
Regardless of the method chosen, human error persists 
as the optimum tumour boundaries have to be chosen 
either by eye or automatically (automatic detection was 
very inconsistent). Each of the manufacturer’s software 
removes background signal when gating images, mak-
ing assessment of where the actual signal starts chal-
lenging. By analysing the raw TIF files in 3D using our 
applet developed in Mathematica, we found it easier to 
determine tumour boundaries when able to simultane-
ously view background signals, meaning that the process 
of gating the images is not required. This suggests that 
improvements made in the software of each of these plat-
forms could lead to more accurate results and less bias 
by the researcher in gating for subsequent quantification.
Previous experiments by Lai et  al. [20] showed that 
iRFP was more reliable and more sensitive to detect 
early changes in tumour growth than calliper measure-
ments. Our experimental setup for the subcutaneous 
tumours did not allow strong conclusions to be drawn 
over the sensitivity of iRFP measurements in subcutane-
ous growth between the 3 platforms. However, we were 
able to show that the BIX and LPT platforms were able 
to image liver and bone tumours early and reliably from 
tail vein injected H1299 cells. H1299 administered in the 
blood of mice have previously been shown to settle in the 
liver, brain, ovaries, bone and most predominantly in the 
lung [25]. Remarkably, lung tumours were not detected in 
whole body scans in our study, despite the fact that we 
could detect them ex vivo in these organs. The chest wall 
forms a barrier for detecting fluorescent signals, but Lai 
et al. previously reported iRFP signals from lung tumours 
using whole body imaging [20]. However, their work also 
reveals that iRFP signal is quenched by the chest wall 
and reduced with the depth of tumours, suggesting that 
the tumours we detected post mortem in the lung were 
too small to be detected in the whole-body scan. We did 
detect liver and bone tumours, but we did not detect any 
brain tumours in either the whole-body scans, the ex vivo 
images, or by post mortem examination.
We found that some imaging platforms were unable to 
detect certain tumours. This is important in any experi-
ments in which missing a lesion could be crucial to the 
outcome. Differences between machines could be due to 
the detector being positioned above the imaging bed or 
below. In the LPT and the XVI, the detector is positioned 
above the mice, whereas the detector of the BIX it is posi-
tioned below the imaging bed, resulting in compression 
of the skin and organs, potentially reducing scattering 
and absorption of light with the consequence of some 
tumours being undetected. The BIX imaging arrange-
ment, however, may also provide a level of consistency 
which the other platforms may be missing. Because the 
animal is flattened against the glass, this allows for a 
greater consistency of limb placement than in the LPT or 
BIX when not using tape to secure. Surprisingly, despite 
the more fixed body position, the BIX did not detect 
more tumours than the LPT and missed tumours as often 
as the LPT, reinforcing the idea that the LPT was more 
sensitive in picking up tumours. The mixed effects of 
organ movement and limb placement are hard to untan-
gle, but it is clear that both cause variation in detecting 
deep tissue iRFP signals.
Despite the fact that we could not capture images on 
day 14 of the XVI, our results suggest that both the LPT 
and the BIX were more sensitive in picking up deep tis-
sue tumours earlier than the XVI. LPT marketing indi-
cates that low background signal is achieved through a 
monochromatic near-infrared laser, which might give the 
LPT a detection advantage. In addition, the XVI seemed 
to have higher background levels during ex  vivo imag-
ing compared to the other platforms. We used higher 
binning settings in the XVI that were recommended by 
other users to enable earlier detection of tumours, albeit 
at the loss of resolution. The individual imaging of organs 
has shown that even with a high binning of 8 × 8, the 
XVI has enough resolution to detect smaller lesions in 
the liver (e.g. mouse 12 compared to the other platforms, 
Fig. 4a), suggesting that this high binning did not underlie 
the lack of detecting tumours. Notably, however, because 
each mouse had a slightly different pattern of tumours, 
these mice cannot be counted as replicates, and we can 
therefore not draw conclusions about the general reli-
ability of the platforms in these settings. Instead, we have 
a real-world scenario in which each mouse is imaged 
only once at each timepoint and many slightly different 
mice. The results of missing tumours can therefore be 
seen as an example of data which may have been missed 
during a routine study, and a sufficient reason to ensure 
that multiple images were taken for each animal at each 
time point. Additionally, we only imaged our animals in a 
supine position. It is conceivable that other tumours may 
have been detected if the mice were imaged in different 
positions.
Each platform displayed strengths and weaknesses 
throughout our testing. All platforms are well suited to 
measure subcutaneous growth, but the LPT had the 
highest dynamic range in our dilution series tests. More 
importantly, when imaging organs and deep tissue 
tumours the BIX and the LPT performed slightly better 
in detecting more tumours and the resolution of the LPT 
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allowed to see more details of small tumours in lungs 
post mortem. It is worrying that mice had many small 
lung tumours that were not seen in any of the platforms 
in the whole-body scans. The question is whether other 
techniques would have picked these up and whether MRI 
or luciferase are better for detecting deep-tissue tumours 
earlier.
Our results as a whole conclude that iRFP imaging, 
growing in popularity, is a good non-invasive method for 
tracking tumour growth, though it also serves as a warn-
ing that care must be taken when using this method. Our 
findings show that different platforms can give different 
answers about the magnitude of growth of subcutaneous 
tumours, and can also detect deeper tumours differently 
from one another. Researchers should consider different 
solutions for obtaining information from raw images as 
taken from the platforms. Our results using Mouseten-
sity, the Mathematica package which we developed 
show that we were able to extract more comparable data 
between platforms, and use our own approach to image 
segmentation which we found to be more reliable. As the 
use of this technology continues to expand, we hope that 
researchers will take these findings on board, leading to 
more reliable results.
Methods
Stable cell line creation
iRFP 713 was a kind gift from Drs A. Hock and K Vous-
den. H1299 and A431 cells were obtained from ATCC 
(www. ATCC. org), authenticated using STR profiling 
and checked against the ATCC reference and screened 
against mycoplasm. Cells were grown in DMEM (Gibco) 
supplemented with FBS (Sigma) at 37° and transfected 
with iRFP713 (Ex688, Em713) using lipofectamine 2000 
(ThermoFisher Scientific) according to the manufactur-
er’s instruction. iRFP in cells is then expressed under a 
CMV promotor and stable cells were generated by grow-
ing cells in 96-well plates in serial dilutions and identify-
ing positive clones using the Li-Cor Odyssey Sa platform. 
Clones with the highest expression levels were selected 
for further studies.
Creation of imaging test plate
A confluent T75 flask of iRFP-expressing A431 cells 
was trypsinised (ThermoFisher Scientific), pelleted and 
fixed with 4% paraformaldehyde in PBS (10  min). The 
fixed cells were resuspended in 1.5  ml of pre-warmed 
0.5% agarose (Invitrogen). Similarly, 5  µl of IRDye 
680RD antibodies (Li-Cor) were diluted into 1.5  ml of 
agarose. The resulting solutions were then used to cre-
ate tenfold serial dilutions. 450 µl of each solution was 
used to fill triplicate wells in a black 96-well CellCar-
rier plate (PerkinElmer) and allow to solidify at RT. 
Wells were over-filled to form convex menisci which 
were then sliced off to create uniform flat surfaces. To 
allow each platform to perform optimally, the acquisi-
tion settings were changed between iRFP and 680RD 
acquisition (Additional file  2: Table  S2). Of note, both 
were imaged with the same settings on the LPT, since 
no settings other than binning can be changed on this 
platform. Images were analysed separately with each 
platform’s image analysis software. Average and SD 
were calculated using GraphPad Prism v9.
Animals and tumour formation
All procedures involving mice were carried out under 
the UK Home Office project licence number P449972E8. 
Female NOD SCID gamma mice (JAX NSG) were 
obtained from internal breeding colonies. Upon arrival 
mice were acclimatised for one week. Experiments com-
menced when they were between 42 and 46 days old and 
weighing over 20 g. All mice appeared in good health and 
were randomly allocated to the groups by an independent 
technician not involved in our study. Mice were kept in 
groups of 3 per cage (tecniplast Blue-line IVC) with food 
(irradiated RM-3, SDS), environmental enrichment (nest-
ing material, cardboard tunnels, wooden chew sticks, 
hemp nestlets and handling tunnels) and water (filtered 
0.2 micron, bottle change 2 × per week) ad libitum with 
Datesand Fibreton 6 as bedding. Weight was recorded 
twice per week. Tumour burden was monitored twice per 
week, until palpable, then calliper-measured twice per 
week. Tumour volume was estimated by using the formula 
(length ×   width2)/2. 12 mice were used overall, with 6 
receiving injections leading to subcutaneous tumours, 
and 6 receiving tail-vein injections to lead to a metas-
tasis-like model. Previous calculations using imaging 
mCherry had shown that 6 mice were sufficient to show 
differences in xenograft growth using in vivo imaging in 
a relevant cancer setting [29]. For subcutaneous and tail 
vein injections, cells were tested for mycoplasma prior 
to the procedure. A total of 2 ×  106 H1299 cells in 100 μl 
50% geltrex/PBS (Gibco) were injected subcutaneously 
into the left flank of another 6 mice (1–6). A total of 
2 ×  106 H1299 cells in 100 μl PBS were injected into the 
tail vein of 6 mice (7–12). Calliper measurements were 
performed independently by blinded mouse husbandry 
specialists. The timeline of callipers and imaging was set 
before the experiment commenced and due to availability 
in the imaging room unable to be performed on the same 
day. Calliper measurements were done prior to imaging 
the following day. NSG Mice were chosen because they 
are a commonly used model to study the growth and 
spread of xenograft tumours. No animals were excluded 
from this study.
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Determination of intra‑platform signal variation
To determine the level of signal variation found within 
each platform, we used the XFM-2 phantom mouse car-
rying an Alexa Fluor 680 emitter (Caliper LifeSciences). 
The phantom was repeatedly imaged with each platform 
to introduce variation. The phantom was placed ran-
domly, repeatedly into different positions by varying the 
height and rotation of the phantom, as well significantly 
changing the position and rotation of the emitter (180° 
rotations, and up to 5 mm changes in depth) in order to 
maximise variations.
In vivo imaging of iRFP
Prior to imaging, mouse anaesthesia was induced using 
4 L/min of oxygenated Isoflurane (Merial Animal Health, 
50,878) and maintained (2 L/min) in the imaging plat-
forms (37 °C) using the platform-specific nose cones. For 
the Xenogen VivoVision IVIS 200 (XVI) and the Bruker 
in-Vivo Xtreme (BIX), anaesthetised mice were placed in 
groups of 3 and for the Li-Cor Pearl Trilogy (LPT) indi-
vidually, according to their cage number, into the cham-
ber and aligned with the nose cones, or in the case of the 
XVI, the laser guided field of view. Mice with subcutane-
ous tumours were placed on their side with the flank con-
taining the tumour facing the camera. Tail vein injected 
mice were placed dorsally in the XVI and LPT and ven-
trally in the BIX, in order for the abdomen to face the 
camera. Brightfield and fluorescent images were obtained 
with each machine. Image acquisition settings were ini-
tially based on feedback/recommendations by regular 
users of each platform, or from sales representatives. The 
LPT was set to a “medium” binning (2 × 2), the XVI was 
set to “medium” binning (binning of 8 × 8) and the BIX 
acquired images without binning Imaging operators were 
blinded by ensuring that they had not looked at the pre-
vious days’ image before taking the current image. Sepa-
rate operators placed the mouse, and took the image so 
that only the former needed to know which mouse was 
being imaged. Imaging was performed in a 2-week period 
when all platforms were available, for fairest compari-
son. We set imaging frequency at twice per week to allow 
mice time to recover from anaesthesia.
Image analysis
In line with best practice, backgrounds were first defined 
on each mouse using an ellipse tool, selecting a region 
similar in size to the tumour but in an area with only 
background signal at the shoulder contralateral to the vis-
ibly positive signals. The threshold for visualisation was 
set individually for each mouse so that the tumour was 
visible on the first day of measurements. This threshold 
was applied to each image of this mouse across each day. 
This process was repeated for each mouse. The tumour 
regions were then defined using the freehand tool, as 
the available automatic selection tools were unreliable 
and variable. Values were then extracted from the soft-
ware and analysed using GraphPad Prism v9. To calcu-
late tumour intensities from each mouse independently, 
we created a Wolfram Mathematica applet [Wolfram 
Research, Inc., Mathematica (Version 12.1, Champaign, 
IL (2020))], to make 3D models of the signal and to calcu-
late tumour intensities.
3D interpretations of the infrared data were generated 
from TIF files generated by each platform. Raw TIFs were 
first cropped to show only the tumour and a small area 
around it, taking care to ensure that the cropped area was 
approximately the same size each time. The TIFs were 
then loaded into the Mathematica Applet (MouseTensity) 
where the pixel values were normalised to lie within the 
range 0 to 1. A rotatable 3D plot was then generated by 
plotting the (normalised) intensity as the Z-axis, which 
enabled the visualisation of the entire mouse, including 
clear definition of the fur, as the background intensity is 
related to the distance from the detector. This allowed 
us to create a plane through the 3D plot, in a similar way 
to that which is done in the proprietary software for all 
three imaging platforms, but with the benefit of an eas-
ier visualisation of the surrounding area. This plane can 
then be moved vertically until the plane transcribes the 
3D object in a shape defining the boundaries of the sig-
nal produced by the tumour, separating it from the rest 
of the body of the mouse. An initial value for this plane 
is provided via a thresholding method based on enthalpy, 
which could then be adjusted by the user [30]. This cut-
off is then used to define the area on the TIF which is 
considered to be the signal, and then all measurements 
are taken directly from the raw, unscaled, image. The 
height of the plane on the z-axis can be used to deter-
mine the level of signal above the background, which can 
then be subtracted. This applet is deposited on: https:// 
zenodo. org/ record/ 43350 47.
Histology
Livers and lungs were fixed in formalin, cut and stained 
for H&E. Slides were scanned in the Olympus VS200.
Statistics
GraphPad Prism 9 was used make graphs and to calcu-
late statistical differences using a one-way ANOVA as 
described in the figure legends. P-values of less than 0.05 
were considered statistically significant.
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17. The units for the x- and y-axes are pixels, and standardised units for 
the z-axis. Figure S3 (A-C) Tumour intensity images generated using our 
Mathematica MouseTensity software. Subcutaneous tumours from all 
6 mice were imaged using all 3 platforms (A) XVI, (B) BIX, (C) LPT on day 
24. The units for the x- and y-axes are pixels, and standardised units for 
the z-axis. Figure S4 (A) Example of saturated pixels detected in the XVI 
(Mouse 1 and 4). Only the saturated pixels are shown on the right and 
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low level of saturation, but this would still affect final quantification, while 
mouse 1 day 24 is representative of an obvious overexposure (B-D). Line 
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in each mouse. These are the same data as Fig. 1E-G, but are now shown 
as lines, coloured per mouse. (E) Calliper measurements coloured to show 
growth of tumours over time. These are the same data as Fig. 1B, but are 
now shown as lines, coloured per mouse. Figure S5. (A) Examples of full 
body images of all mice on the last day of imaging on each platform. (B) 
Brightfield images of excised organs, taken in the LPT. Liver and lungs are 
shown for all mice, and front paw and knee that clearly showed a signal is 
shown for mouse 8. Figure S6. Fluorescent images of the knee and front 
paw of mouse 8 in all imaging platforms. 
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in quotations is naming provided by software. Table S3 Statistics from 
Figure 1 EFG. Full statistical output from ANOVA, with Tukey comparisons. 
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percentages of the total number of tumours detected by each platform. 
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